5-year results from the PROUD-PV and CONTINUATION-PV studies

Ropeginterferon alfa-2b is a novel pegylated recombinant interferon, approved in the EU as monotherapy for the treatment of adults with...

Results from an ongoing phase II study of IMG-7289 (bomedemstat) in patients with advanced MF

Many patients with myelofibrosis (MF) become intolerant or resistant to currently approved JAK inhibitors,...

ASH 2020 | Practice-changing abstracts in myeloproliferative neoplasms

The world-leading experts in MPN shared the top abstracts from ASH 2020 that they believe could have the greatest impact on...

Is the hepcidin-mimetic PTG‑300 a promising treatment for therapeutic phlebotomy-dependent PV?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to...

5-year results from the PROUD-PV and CONTINUATION-PV studies

Ropeginterferon alfa-2b is a novel pegylated recombinant interferon, approved in the EU as monotherapy for the treatment of adults with...

ASH 2020: Highlights for polycythemia vera

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital,...

Interferon therapy in the management of myeloproliferative neoplasms

Treatment with interferon (IFN) therapy is considered successful for patients with myeloproliferative neoplasms (MPN), such as...

Ropeginterferon alfa-2b is effective and safe in patients older than 60 years with PV

As discussed in our last editorial theme, the pegylated forms of interferon-alpha improve treatment compliance...

Predicting transition in prefibrotic myelofibrosis

With the 2016 revision to the World Health Organization classification of myeloproliferative neoplasms (MPN), patients with prefibrotic primary...

Applying prognostic models for myelofibrosis in practice

The review by How et al. covers established and emerging prognostic models for PMF.

The practical use of myelofibrosis genomics in a clinical setting

Myelofibrosis (MF), a subtype of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), is characterized by Janus...

Understanding the pathology of MPN: The value of in vivo and in vitro models

Among chronic Philadelphia-negative myeloproliferative neoplasms (MPN), polycythemia vera (PV) is considered the most...